Lantheus Holdings, Inc. (NASDAQ:LNTH) is Portolan Capital Management LLC’s Largest Position

Portolan Capital Management LLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 6.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 670,881 shares of the medical equipment provider’s stock after buying an additional 38,776 shares during the quarter. Lantheus comprises approximately 5.3% of Portolan Capital Management LLC’s holdings, making the stock its largest position. Portolan Capital Management LLC’s holdings in Lantheus were worth $73,629,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Signaturefd LLC grew its holdings in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares in the last quarter. GAMMA Investing LLC raised its stake in Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares in the last quarter. UMB Bank n.a. raised its stake in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. Kathleen S. Wright Associates Inc. purchased a new stake in Lantheus during the third quarter valued at $51,000. Finally, Nkcfo LLC purchased a new stake in Lantheus during the second quarter valued at $47,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. JMP Securities decreased their price target on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Truist Financial reissued a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $125.71.

Lantheus Price Performance

LNTH stock opened at $88.51 on Wednesday. The company has a market capitalization of $6.15 billion, a PE ratio of 14.73 and a beta of 0.45. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The firm’s 50-day moving average is $100.44 and its 200 day moving average is $97.49.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.